AbbVie announced that its experimental eczema drug, upadacitinib, met the main goal in a mid-stage study. The positive news brought down competitor Regeneron Pharmaceuticals' stocks, according to a Reuters article. Regeneron’s eczema drug, Dupixent, was approved by the U.S. FDA in March.
AbbVie’s mid-stage trial data for upadacitinib seemed comparable to Dupixent’s late-stage data, but the two studies had different sample sizes, making direct comparisons hard to measure, said Jefferies analyst Berin Amin. He still expects the drugs to compete, however.
Upadacitinib showed a statistically significant improvement in reducing both the severity of eczema in patients and the amount of body area affected by the disease, AbbVie said.
Read the full story